Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Tee

Cardiovascular Disease Vero Beach, FL Medical Doctor

NPI 1972543486 CMS profile 362297

960 37Th Pl, Suite 105, Vero Beach, FL 32960

Open in the dashboard

General payments

$38,760

853 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,282 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Howard Tee of Vero Beach, FL is reported in the CMS Open Payments database as having received $38,760 across 853 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,282 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,989 89
2024 General $3,768 103
2023 General $5,488 117
2022 General $3,397 145
2021 General $4,931 140
2020 General $1,731 96
2019 General $17,456 163

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Tee
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Howard Tee were reported at $1,989. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Howard Tee Cardiovascular Disease median Middle half National median
2019 $17,456 $450 $127–$1,392 $163
2020 $1,731 $242 $77–$751 $114
2021 $4,931 $335 $101–$1,037 $132
2022 $3,397 $395 $121–$1,211 $149
2023 $5,488 $443 $136–$1,283 $160
2024 $3,768 $450 $136–$1,323 $164
2025 $1,989 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $14,007 88 payments
  2. Novo Nordisk Inc $2,595 25 payments
  3. Boston Scientific Corporation $2,116 13 payments
  4. CVRx, Inc. $2,101 29 payments
  5. Medtronic Vascular, Inc. $2,056 13 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $1,873 72 payments
  7. Abbott Laboratories $1,115 27 payments
  8. Pfizer Inc. $1,051 70 payments
  9. Amgen Inc. $1,043 53 payments
  10. AstraZeneca Pharmaceuticals LP $1,028 44 payments
  11. Other $9,775 419 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,249 816 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,200 5 payments
  3. Travel and Lodging $3,674 9 payments
  4. Consulting Fee $2,115 3 payments
  5. Education $522 20 payments
Products named General payments · program years 2019–2025
  1. XARELTO $13,985 86 payments
  2. Ozempic $2,383 16 payments
  3. Barostim Neo System $2,101 29 payments
  4. Reveal LINQ $2,054 12 payments
  5. WATCHMAN Access System $1,875 7 payments
  6. JARDIANCE $1,227 48 payments
  7. VERQUVO $1,136 52 payments
  8. Repatha $963 48 payments
  9. Livalo $758 45 payments
  10. ELIQUIS $712 50 payments
  11. Other $14,786 603 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 148 drugs

Part D claims

17,665

Median for Cardiology: 2,533

Drug cost

$3,745,066

Median for Cardiology: $485,213

Branded share of claims

30.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,405 $1,598,157
Xarelto Rivaroxaban Brand 530 $602,817
Entresto Sacubitril/Valsartan Brand 304 $358,008
Jardiance Empagliflozin Brand 201 $208,966
Ozempic Semaglutide Brand 72 $96,120
Repatha Syringe Evolocumab Brand 97 $80,558
Multaq Dronedarone Hcl Brand 51 $71,244
Mounjaro Tirzepatide Brand 60 $67,063
Farxiga Dapagliflozin Propanediol Brand 74 $60,060
Repatha Sureclick Evolocumab Brand 77 $56,501

The 10 drugs with the highest cost, of 148 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$1,464,141

Of which drugs: $3,425

Medicare patients

1,998

Average age 79

Services billed

20,311

1,036 women, 962 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 42%
Atrial fibrillation 38%
Diabetes 29%
Chronic kidney disease 26%
Heart failure 25%
Cancer 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) J0153 Office 106 6,360 $2,628
Injection, regadenoson, 0.1 mg J2785 Office 86 344 $797

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
$204 174 —
VERQUVO
$189 17 —
XARELTO
$150 530 —
LEQVIO
$147 — —
MULTAQ
$98 51 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

853 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record